The European Union and the United States delivered on a significant element of the Joint Statement agreed by Presidents Juncker and Trump in July 2018, that includes a commitment from both sides to reduce barriers and increase trade in a range of sectors, including pharmaceuticals.
This EU-U.S. Mutual Recognition Agreement is underpinned by robust evidence that the EU and the U.S. have comparable procedures to carry out good manufacturing practice inspections for human medicines, and will expan...


This story is part of New Europe's Premium content.

To Read the Full Story, Subscribe or Sign In from the ↑ Top of the Page ↑
new europe join now